Cue Biopharma, Inc. (CUE) Reports Q3 Loss, Lags Revenue Estimates

分组1 - Cue Biopharma reported a quarterly loss of $0.07 per share, better than the Zacks Consensus Estimate of a loss of $0.10, and improved from a loss of $0.17 per share a year ago, resulting in an earnings surprise of +30.00% [1] - The company posted revenues of $2.15 million for the quarter ended September 2025, missing the Zacks Consensus Estimate by 14.04%, and down from $3.34 million in the same quarter last year [2] - Cue Biopharma shares have declined approximately 37.3% year-to-date, contrasting with the S&P 500's gain of 16.4% [3] 分组2 - The current consensus EPS estimate for the upcoming quarter is -$0.11 on revenues of $2.5 million, and for the current fiscal year, it is -$0.45 on revenues of $8.4 million [7] - The Medical - Biomedical and Genetics industry, to which Cue Biopharma belongs, is currently ranked in the top 34% of over 250 Zacks industries, indicating a favorable outlook compared to lower-ranked industries [8]